Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2001

View Archived Issues

Changes to Exelon product labeling announced by Novartis

FDA approves vagus nerve stimulation trial for anxiety disorders

Neotrofin increases number of brain stem cells in preclinical models

Split-dose schedule of RPR-109881A explored in phase I trial in Canada

Beta2-agonists inhibit eotaxin release from human airways smooth muscle cells

EMEA begins review of Trisenox for APL indication

Two innovative fertility products launched by Serono in U.S.

FDA issues approvable letter for Visudyne

AOD-9604 safely reduces body weight gain in animal model of obesity

Phase I evaluation of Palatin's PT-141 for ED commences

Antiinfective alliance established by IntraBiotics and Albany Molecular Research

Influence of EGIS-7229 on myocardial refractoriness to electrical stimulation

ArQule/Camitro merger complete

IMC-C225 granted fast track designation for refractory colorectal carcinoma

CoPharma licenses anticancer compound from Dana-Farber

Suntory to codevelop SUN-N8075 with Taisho

Nabi provides update on StaphVAX progress

Overseas development of TR-14035 to be managed by GlaxoSmithKline

Compositions and methods of treating obesity claimed by Knoll

Roche describes new series of subtype-selective NMDA receptor antagonists and use thereof

Polyketide macrolides produced by mycobacteria exert anticancer, antiinflammatory effects

Bispidine antiarrhythmic agents from AstraZeneca

Yamanouchi compound stimulates skeletal muscle glucose uptake via effect on GLUT4

Bristol-Myers Squibb presents new anti-HIV agents in recent patent

Novel 5-HT2C receptor ligands in the Pharmacia pipeline

Metallo-beta-lactamase inhibitors synthesized and tested at Merck & Co.

HIV protease inhibitors with a sulfonamide structure prove highly active against resistant virus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...